Miragen Therapeutics, Inc. (MGEN): Price and Financial Metrics

Miragen Therapeutics, Inc. (MGEN)

Today's Latest Price: $0.51 USD

0.02 (4.65%)

Updated Oct 26 9:40am

Add MGEN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

MGEN Stock Summary

  • MGEN has a higher market value than just 10.49% of US stocks; more precisely, its current market capitalization is $28,248,467.
  • Revenue growth over the past 12 months for Miragen Therapeutics Inc comes in at -40.29%, a number that bests just 5.85% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MGEN comes in at -71.31% -- higher than that of only 6.17% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Miragen Therapeutics Inc, a group of peers worth examining would be DTIL, ORMP, PIRS, JNCE, and KALV.
  • Visit MGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.miragen.com.

MGEN Stock Price Chart Interactive Chart >

Price chart for MGEN

MGEN Price/Volume Stats

Current price $0.51 52-week high $2.27
Prev. close $0.49 52-week low $0.31
Day low $0.50 Volume 139,807
Day high $0.53 Avg. volume 2,151,067
50-day MA $0.80 Dividend yield N/A
200-day MA $0.83 Market Cap 29.03M

Miragen Therapeutics, Inc. (MGEN) Company Bio

Miragen Therapeutics, Inc., a clinical stage biopharmaceutical company, develops microRNA-targeted therapies for various unmet medical needs. It focuses on various therapeutic areas, such as cancer, pathologic fibrosis, neuro-inflammatory, and cardiovascular diseases. The company was founded in 2006 and is based in Boulder, Colorado.

MGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

MGEN Latest Social Stream

Loading social stream, please wait...

View Full MGEN Social Stream

Latest MGEN News From Around the Web

Below are the latest news stories about Miragen Therapeutics Inc that investors may wish to consider to help them evaluate MGEN as an investment opportunity.

miRagen Therapeutics' (MGEN) CEO Bill Marshall on Q2 2020 Results - Earnings Call Transcript

miRagen Therapeutics, Inc. (MGEN) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Dan Ferry – Managing Director-LifeSci Advisors Bill Marshall – President and Chief Executive Officer Diana Escolar – Chief Medical Officer Jason Leverone – Chief Financial Officer Conference Call Participants Jonathan Miller – Evercore...

SA Transcripts on Seeking Alpha | August 5, 2020

Miragen Therapeutics leads healthcare gainers; Mallinckrodt and Vaxart among losers

Gainers: Miragen Therapeutics (MGEN) +31%. Oncternal Therapeutics (ONCT) +20%. NuCana (NCNA) +18%. PolarityTE (PTE) +12%. Castlight Health (CSLT) +12%.Losers: MYOS RENS Technology (MYOS) -10%. Vaxart (VXRT) -9%. Eyenovia (EYEN) -9%. Mallinckrodt (MNK) -9%. Milestone Pharmaceuticals (MIST) -7%....

Seeking Alpha | July 24, 2020

Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma

BOULDER, Colo., July 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma. Cobomarsen is an inhibitor of miR-155 currently being developed by miRagen in two clinical programs to address different types of T-cell lymphoma, including a Phase 2 trial for cutaneous T-cell lymphoma (CTCL) and a Phase 1 trial for adult T-cell leukemia/lymphoma (ATLL). “This is an important milestone in the development of cobomarsen. We believe the FDA’s decision to grant cobomarsen orphan drug designation underscores the need for new tre...

Yahoo | July 23, 2020

miRagen to Report Second Quarter 2020 Financial Results on August 5, 2020

BOULDER, Colo., July 22, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its second quarter 2020 financial results after the financial markets close on Wednesday August 5, 2020.   The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Wednesday August 5, 2020. To access the call, please dial 877-407-0789 in the U.S. or 201-689-8562 outside the U.S. and provide the conference ID number: 13706539. To access the live webcast, please go to the investors section of miRagen’s website at http://investors.miragen.com/events. Following the live webcast, an archived version of the call will b...

Yahoo | July 22, 2020

miRagen Regains Compliance With Nasdaq Listing Requirements

BOULDER, Colo., July 02, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that on July 1, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with the applicable Nasdaq minimum bid price continued listing requirement and the matter is now closed. The Company had previously been notified by Nasdaq on October 28, 2019 that it was not in compliance with the minimum bid price requirement because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.

Yahoo | July 2, 2020

Read More 'MGEN' Stories Here

MGEN Price Returns

1-mo -36.89%
3-mo -54.46%
6-mo -16.39%
1-year -35.52%
3-year -93.85%
5-year -96.09%
YTD 6.27%
2019 -84.16%
2018 -70.95%
2017 108.18%
2016 -55.47%
2015 -70.47%

Continue Researching MGEN

Want to see what other sources are saying about Miragen Therapeutics Inc's financials and stock price? Try the links below:

Miragen Therapeutics Inc (MGEN) Stock Price | Nasdaq
Miragen Therapeutics Inc (MGEN) Stock Quote, History and News - Yahoo Finance
Miragen Therapeutics Inc (MGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8085 seconds.